Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Telix Pharmaceuticals Ltd. ( (AU:TLX) ) is now available.
Telix Pharmaceuticals Ltd. reported a significant 62% year-over-year increase in Q1 2025 revenue, reaching $186 million, driven by strong sales of Illuccix® and contributions from the recent acquisition of RLS Radiopharmacies. The company reaffirmed its FY 2025 revenue guidance and highlighted strategic expansions, including new market approvals and acquisitions, which are expected to enhance its global footprint and product offerings. The launch of Gozellix® in the U.S. and advancements in its therapeutic pipeline, such as the development of a new generator technology for lead-212, underscore Telix’s commitment to innovation and growth in the radiopharmaceutical sector.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. is a company operating in the biopharmaceutical industry, specializing in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. The company focuses on innovative imaging and treatment solutions for cancer, with products like Illuccix® and Gozellix® targeting prostate cancer imaging and therapy.
YTD Price Performance: 15.25%
Average Trading Volume: 5,037
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.55B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.